Epigral543332Earnings call transcript
Q2 FY27 call: revenue INR752 crores, PAT INR64 crores; CPVC and Epichlorohydrin plants near commissioning
Epigral has shared the transcript of its earnings call held on 2 November 2026 to discuss Q2 FY27 results.
By ScoutQuest · · 2 min read
INR752 crores+27.7%
Q2 FY26INR589 croresQ2 FY27INR752 crores
- Q2 FY27 Revenue
- INR752 crores against INR589 crores a year earlier
- Q2 FY27 PAT
- INR64 crores
- Derivatives & Specialty Share of Q2 Revenue
- 57% of Q2 revenue
What the quarter looked like
- Revenue was INR752 crores in Q2 FY27, compared with INR589 crores in the same quarter a year earlier.
- EBITDA was INR136 crores and profit after tax was INR64 crores.
- For the first half of FY27, revenue was INR1,461 crores and PAT was INR164 crores.
Mix is shifting towards derivatives
- Derivatives and specialty products contributed 57% of Q2 FY27 revenue.
- Management said this contribution will keep rising as the new capital projects come on stream, which also broadens the customer base.
Where the pressure comes from
- Management described the operating environment as volatile and challenging, saying headwinds may continue into the coming quarters.
- Margins were squeezed by a lag in passing through volatile feedstock prices, and by higher freight rates, longer lead times and rising domestic transport costs.
- The West Asia situation was cited as a factor behind high raw material prices affecting margins.
- Management said the first half is typically an off-season for some products and the second half usually performs better, so it retains a positive outlook for H2 FY27.
Project pipeline
- The CPVC and Epichlorohydrin capacity expansions are in their final stages, with trial runs currently underway; both plants are expected to be commissioned within a quarter.
- The epoxy resin and formulations project and the multi-purpose plant (MPP) project, approved by the Board last quarter, are moving ahead as planned.
- Pilot plants for both are ready and the customer approval process will begin soon, which management expects to shorten qualification timelines once commercial production starts.
Balance sheet
- Net debt stood at INR514 crores as on 30 September 2026, and management described debt levels as comfortable.
How a retail investor can read this
- The transcript shows a company growing revenue and profit while its margins are under pressure from input and logistics costs, a mix that depends on how quickly costs can be passed on.
- The near-term triggers management pointed to are the commissioning of the CPVC and Epichlorohydrin plants, the start of customer approvals for the new epoxy and MPP projects, and the usual second-half improvement in demand.
What to watch
- Progress on commissioning the two new plants and the start of commercial production.
- Movement in raw material and freight costs, and whether price increases keep pace.
- The pace of customer approvals for the epoxy and multi-purpose plant products.
57%Derivatives and specialty share of revenue
Also from Epigral
Epigral schedules one-on-one video-conference meeting with Kotak Mahindra Asset Management (Singapore) on 19 Nov 2026
17 Nov 2026
Epigral schedules one-on-one video conference with Kitara Capital on 20 November 2026
17 Nov 2026
Epigral management discussed FY27 margin guidance and inventory/debtor day improvements, with stock recovering from day's lows
3 Nov 2026
More numbers
- Q2 FY27 revenueINR752 crores
- Q2 FY26 revenueINR589 crores
- Q2 FY27 EBITDAINR136 crores
- Q2 FY27 PATINR64 crores
- H1 FY27 revenueINR1,461 crores
- H1 FY27 PATINR164 crores
- Derivatives and specialty share of Q2 FY27 revenue57%
- Net debt as on 30 September 2026INR514 crores
Source: BSE · 7 Nov 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.